Ensysce Biosciences (ENSCW) Cash & Equivalents (2017 - 2025)

Ensysce Biosciences (ENSCW) has 9 years of Cash & Equivalents data on file, last reported at $4.3 million in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $4.3 million, up 23.08% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.3 million (up 23.08% YoY), and the FY2025 annual result was $4.3 million, up 23.08% from the prior year.
• Cash & Equivalents improved to $4.3 million in Q4 2025 per ENSCW's latest filing, from $1.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $12.3 million in Q4 2021 and troughed at $1.0 million in Q2 2024.
• A 5-year average of $4.6 million and a median of $3.5 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2023: Cash & Equivalents jumped 12697.56% in 2021, then tumbled 83.23% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $12.3 million in 2021, then slumped by 74.34% to $3.1 million in 2022, then tumbled by 64.3% to $1.1 million in 2023, then soared by 211.68% to $3.5 million in 2024, then advanced by 23.08% to $4.3 million in 2025.
• Business Quant data shows ENSCW's Cash & Equivalents at $4.3 million in Q4 2025, $1.7 million in Q3 2025, and $2.2 million in Q2 2025.